---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000006"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:54:26.606684+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novocure reports preliminary FY2022 net revenue $537.8M (+1% YoY); LUNAR study meets primary endpoint

## Summary
- FY2022 net revenue $537.8M, +1% YoY; Q4 net revenue $128.4M, with US $98.6M, EMEA $17.0M, Japan $7.9M, Greater China $4.9M.
- Cash, equivalents and short-term investments $969.4M as of Dec 31, 2022.
- 3,430 active patients; 1,373 prescriptions received in Q4 (North America 956, EMEA 312, Japan 105).
- LUNAR study met primary endpoint: significant overall survival benefit with TTFields + immune checkpoint inhibitors in NSCLC.
- New thinner/lighter arrays launched in Europe under limited market release; Health Canada approved Optune for GBM.

## SEC filing metadata
- accession: 0001645113-23-000006
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/0001645113-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/nvcr-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000006
- JSON: https://secwatch.observer/filing/0001645113-23-000006.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000006.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported for the quarter and year ended December 31, 2022 results: revenue $537.8 million.
  - Period: for the quarter and year ended December 31, 2022
  - Revenue: $537.8 million
  - Result: preliminary results
  source text: --- EX-99.1 (EX-99.1) --- Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/0001645113-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.